公开(公告)号：HK1132744A1

公开(公告)日：2010-03-05

申请号：HK10100318

申请日：2010-01-12

Applicant: PHARMACYCLICS INC

Inventor： PAN ZHENGYING ,  LI SHYR JIANN ,  SCHEREENS HELEEN ,  HONIGBERG LEE ,  VERNER ERIK

IPC: C07D20060101 ,  G01N20060101

公开(公告)号：MX2009010284A

公开(公告)日：2010-01-29

申请号：MX2009010284

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: A61K31/52 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  C07D253/06 ,  C07D473/34 ,  C07D487/04

Abstract: En la presente se describen compuestos inhibidores de cinasa irreversibles, métodos para sintetizar dichos inhibidores irreversibles, y métodos para usar dichos inhibidores irreversibles en el tratamiento de enfermedades. En la presente se describen también métodos, ensayos y sistemas para determinar un inhibidor irreversible apropiado de una proteína, que incluye una cinasa.

公开(公告)号：CA2663116A1

公开(公告)日：2008-04-03

申请号：CA2663116

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: A01N43/90 ,  A61K31/519

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyr osine kinase (Btk). Also described are irreversible inhibitors of Btk. Metho ds for the preparation of the compounds are disclosed. Also disclosed are ph armaceutical compositions that include the compounds. Methods of using the B tk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseas es or conditions.

公开(公告)号：AU2006336506A1

公开(公告)日：2007-08-02

申请号：AU2006336506

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： PALMER JAMES T ,  HONIGBERG LEE ,  JANKOWSKI ORION D

IPC: C07D471/06 ,  A61K31/416 ,  A61K31/4375 ,  A61K31/675

Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.